Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

RAYSEARCH Aktie

 >RAYSEARCH Aktienkurs 
17.92 EUR    -1.5%    (TradegateBSX)
Ask: 18.06 EUR / 70 Stück
Bid: 17.94 EUR / 70 Stück
Tagesumsatz: 157 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
RAYSEARCH Aktie über LYNX handeln
>RAYSEARCH Performance
1 Woche: +7,6%
1 Monat: +3,0%
3 Monate: -13,6%
6 Monate: -17,9%
1 Jahr: -17,0%
laufendes Jahr: -14,9%
>RAYSEARCH Aktie
Name:  RAYSEARCH LABS B SK 0,40
Land:  Schweden
Sektor:  Gesundheit
ISIN/ Wkn:  SE0000135485 / 905265
Symbol/ Ticker:  27R (Frankfurt)
Kürzel:  FRA:27R, ETR:27R, 27R:GR
Index:  -
Webseite:  https://www.raysearchlabs..
Profil:  RaySearch Laboratories AB (publ) is a Sweden-based medical technology company specializing in advanced software solutions for radiation therapy and oncology. Founded in 2000 as a spin-off from the Karolinska Institute in Stockholm, it develops innova..
>Volltext..
Marktkapitalisierung:  622.16 Mio. EUR
Unternehmenswert:  621.01 Mio. EUR
Umsatz:  126 Mio. EUR
EBITDA:  53.08 Mio. EUR
Nettogewinn:  21.35 Mio. EUR
Gewinn je Aktie:  0.62 EUR
Schulden:  37.01 Mio. EUR
Liquide Mittel:  38.18 Mio. EUR
Operativer Cashflow:  36.28 Mio. EUR
Bargeldquote:  0.71
Umsatzwachstum:  19.5%
Gewinnwachstum:  18.59%
Dividende je Aktie:  0.27 EUR
Dividendenrendite:  1.64%
Dividendenschätzung:  2.18%
Div. Historie:  23.05.25 - 0.27123€
23.05.24 - 0.063469€
Insiderhandel:  -
Suchwörter:  RAYSEARCH
Letzte Datenerhebung:  05.04.26
>RAYSEARCH Kennzahlen
Aktien/ Unternehmen:
Aktien: 30.8 Mio. St.
Frei handelbar: 85.98%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 458
Umsatz/Mitarb.: 0.28 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 71.16%
Bewertung:
KGV: 28.76
KGV lG: 24.37
KUV: 4.48
KBV: 6.65
PEG-Ratio: 2.47
EV/EBITDA: 11.7
Rentabilität:
Bruttomarge: 74.23%
Gewinnmarge: 16.94%
Operative Marge: 23.93%
Managementeffizenz:
Gesamtkaprendite: 11.16%
Eigenkaprendite: 24.46%
>RAYSEARCH Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung, Medizinprodukte & -technik/ Implantate/ Wundpflege
 
12.02.26 - 12:24
RaySearch: Umsatzwachstum von 16 % in Q4 2025, Aktie gibt dennoch nach (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
26.09.25 - 09:42
RaySearch Brings Next-Level Innovation to ASTRO 2025 (PR Newswire)
 
STOCKHOLM, Sept. 26, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce its participation at ASTRO in San Francisco, California, September 28-30, where state of the art innovations will be presented under the global campaign Coding Energy to End Cancer. Attendees......
01.09.25 - 11:45
RaySearch launches RayIntelligence® v2025 (PR Newswire)
 
STOCKHOLM, Sept. 1, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) today announced the release of RayIntelligence®* v2025, a major update to its oncology analytics system designed to transform clinical data into actionable insights. With new tools for building customized dashboards......
28.08.25 - 10:06
Proton center in South Korea selects RayStation and RayCare (PR Newswire)
 
STOCKHOLM, Aug. 28, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Keimyung University Dongsan Medical Center (DSMC) in South Korea has selected the treatment planning system RayStation®* and oncology information system RayCare®* to enable advanced......
08.08.25 - 16:00
RaySearch Laboratories GAAP EPS of SEK0.90, revenue of SEK304.9M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.08.25 - 08:21
RaySearch Laboratories: Interim report April - June 2025 (PR Newswire)
 
STOCKHOLM, Aug. 8, 2025 /PRNewswire/ -- SECOND QUARTER (APRIL - JUNE 2025) Order intake amounted to SEK 241.2 M (290.3) Net sales amounted to SEK 304.9 (318.9) Operating profit amounted to SEK 36.4 M (79.3) Profit after tax amounted to SEK 30.8 M (61.4) Earnings per share before/after......
25.07.25 - 11:42
RaySearch to present innovative news in RayStation, RayCare, and RayIntelligence at AAPM 2025 (PR Newswire)
 
STOCKHOLM, July 25, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce its participation at AAPM in Washington, D.C., July 27-30, where state of the art innovations under the global campaign Coding Energy to End Cancer will be presented. Attendees can take part in......
21.07.25 - 08:45
AKSM/Oncology selects RayCare and RayStation for a new cancer center (PR Newswire)
 
STOCKHOLM, July 21, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that AKSM/Oncology has selected RayCare®* oncology information system and RayStation®* treatment planning system for Advanced Radiation Therapeutics (ART), a new partnership with Urology......
18.07.25 - 16:24
RaySearch and Radiology Oncology Systems in strategic partnership to expand access to cancer care (PR Newswire)
 
STOCKHOLM, July 18, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) and Radiology Oncology Systems, Inc. (ROS) are pleased to announce a strategic partnership, aiming at identifying and pursuing opportunities involving both emerging and existing technologies, with focus on the......
18.07.25 - 09:30
Invitation to presentation of RaySearch′s interim report for the second quarter of 2025 (PR Newswire)
 
STOCKHOLM, July 18, 2025 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the second quarter of 2025, on August 8, 2025, at 10.00 am CEST. The report will be published on August 8, 2025, at 07.45 am and will be available......
27.06.25 - 13:18
RaySearch releases RayCare v2025 (PR Newswire)
 
STOCKHOLM, June 27, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces the release of RayCare®* v2025, the latest version of its next-generation oncology information system. The new release delivers powerful functionality enhancements that streamline clinical workflows,......
16.06.25 - 10:06
RayStation used for pioneering clinical milestone at Helsinki University Hospital - first treatment with accelerator-based BNCT in Europe (PR Newswire)
 
STOCKHOLM, June 16, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that RayStation®*, its advanced treatment planning system, was used in the first European clinical treatments with Neutron Therapeutics' accelerator-based boron neutron capture therapy (BNCT),......
16.06.25 - 09:42
RayStation used for pioneering clinical milestone at Helsinki University Hospital – first treatment with accelerator-based BNCT in Europe (Cision)
 
RaySearch Laboratories AB (publ) is pleased to announce that RayStation®*, its advanced treatment planning system, was used in the first European clinical treatments with Neutron Therapeutics' accelerator-based boron neutron capture therapy (BNCT), carried out on a patient at Helsinki University Hospital in Finland. RayStation supports BNCT planning by its suite of tools for patient modelling, plan setup and plan evaluation. In addition, there are specific adaptations for use with the Neutron Therapeutics machine including seamless connection to the BNCT dose engine provided by Neutron...
02.06.25 - 13:21
RaySearch to present advanced software innovations for particle therapy at PTCOG 63 (PR Newswire)
 
STOCKHOLM, June 2, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) will exhibit at PTCOG 63, held June 3-6, 2025, in Buenos Aires, Argentina. At booth #08, the company will showcase its latest software innovations driving the future of particle therapy. RaySearch's portfolio –......
23.05.25 - 00:01
XFRA: DIVIDEND/INTEREST INFORMATION - 23.05.2025 - EQUBF_01 (XETRA)
 
Das Instrument 27R SE0000135485 RAYSEARCH LABS B SK 0,40 EQUITY wird ex Dividende/Zinsen gehandelt am 23.05.2025 The instrument 27R SE0000135485 RAYSEARCH LABS B SK 0,40 EQUITY has its ex-dividend/interest day on 23.05.2025...
22.05.25 - 21:06
Bulletin from the Annual General Meeting 2025 (PR Newswire)
 
The Annual General Meeting 2025 of RaySearch Laboratories AB (publ) was held on May 22, 2025, in Stockholm, Sweden. The following resolutions were adopted. STOCKHOLM, May 22, 2025 /PRNewswire/ -- It was resolved to re-elect Carl Filip Bergendal, Johan Löf, Günther Mårder, Britta Wallgren......
09.05.25 - 18:00
RaySearch Laboratories reports interim report for January 1 to March 31, 2025 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.05.25 - 08:15
Interim report January 1 - March 31, 2025: RaySearch Laboratories (PR Newswire)
 
STOCKHOLM, May 9, 2025 /PRNewswire/ -- FIRST QUARTER (JANUARY - MARCH 2025) Order intake amounted to SEK 409.6 M (238.5) Net sales amounted to SEK 331.7 M (257.2) Operating profit amounted to SEK 74.8 M (45.8) Profit after tax amounted to SEK 56.8 M (36.7) Earnings per share before/after......
03.05.25 - 11:12
RaySearch Laboratories and Vision RT present innovations in surface guided treatment planning at ESTRO (PR Newswire)
 
STOCKHOLM, May 3, 2025 /PRNewswire/ -- At this week's ESTRO conference in Vienna, RaySearch Laboratories AB (publ) and Vision RT proudly announces the next step in their collaboration: the full integration of MapRT with RayStation®* treatment planning system. This integration enables full......
02.05.25 - 15:51
The Royal Marsden first center in the world to treat a patient using the new adaptive replanning module in RayStation for online adaptive radiotherapy treatment (PR Newswire)
 
STOCKHOLM, May 2, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce that The Royal Marsden NHS Foundation Trust in the UK has treated its first patient using a new and groundbreaking workflow, enabled by the new adaptive replanning module, released in the latest......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!